Home/Pipeline/Endoscopic Band Gastroplasty (EBG)

Endoscopic Band Gastroplasty (EBG)

Obesity

Pre-clinicalActive

Key Facts

Indication

Obesity

Phase

Pre-clinical

Status

Active

Company

Endolastic

About Endolastic

Endolastic is a private, pre-revenue medical device company advancing its EndoBand™ platform for endoscopic, band-based interventions. With over 50 successful human cases using its first-generation device, the company is preparing for commercial launch and regulatory filings, supported by a $4M physician-led seed round. Its technology aims to offer a durable, anatomical solution for GERD, obesity, and diabetes, positioned between pharmaceutical therapies and invasive surgery in terms of efficacy, cost, and procedural simplicity.

View full company profile

Therapeutic Areas

Gastroesophageal Reflux Disease (GERD)Obesity Type 2 Diabetes

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active